

Inclusion Criteria

1. Male or female patients, 18 years or older
2. Patients who are registered in the GEDII Registry
3. Steroid-dependent patients with Crohn's disease defined as:
 - ❖ Patients unable to reduce steroids below the equivalent of prednisolone 10 mg/day (or budesonide below 3 mg/day) within 3 months of starting steroids, without recurrent active disease, **or**
 - ❖ Patients who have a relapse within 3 months of stopping steroids. This definition of steroid-dependence requires that the total duration of steroids does not exceed 3 months before a threshold equivalent of prednisolone 10 mg/day is reached.

AND who met one of the following:

- ❖ Active disease (Harvey-Bradshaw Index score ≥ 7 points; moderate to severe symptoms at start of study)
 - ❖ Non active moderate disease (Harvey-Bradshaw Index score ≥ 7 points) with fecal calprotectin levels > 100 ug/g and/or Endoscopic activity (Simple endoscopic score for Crohn's disease [SES-CD] ≥ 3)
4. Patients who have introduced oral azathioprine for the first time according to physician's criteria and with calprotectin levels > 100 ug/g
 5. Patients who gave their informed consent

Exclusion Criteria


1. Patients on methotrexate or under biologics.
2. Any contraindications regarding the use of azathioprine
3. Patients who are being treated with any investigational agent
4. Patients who are not willing to comply with routine clinical appointments

Laboratory Testing

Fecal Samples

- Patients should collect two samples. One for CALEXtube and other for EasySampler Collection Kits
- After IBDoc evaluation, patients should send samples from both tubes (CALEX and easysampler kit) for study team by postmail (a stamped envelope is provided with the kit)
- Samples should be sent within 24 hours
- **Contact GEDII for transport**

Key assessments and time points of data collection



I: Harvey Bradshaw Index; SES-CD: Simple endoscopic score for Crohn's disease; QB: Quantum Blue

For any study related questions, please contact:

Sandra Dias

E-mail: gedi@med.up.pt
Phone number: 912583273

BIOAZA

Title: Impact of AZathioprine in inducing and maintaining clinical, BIOMarkers and endoscopic remission among patients with steroid-dependent Crohn's Disease: a 2-year longitudinal analysis from the GEDII



Study sponsor: Grupo de Estudo da Doença Inflamatória Intestinal (GEDII)

Name of Scientific Coordinator: Prof. Fernando Magro

Primary Objectives

Among patients with Crohn's disease at study inclusion, registered in the GEDII Registry:

- To evaluate the impact of azathioprine in inducing calprotectin remission (calprotectin levels < 200 ug/g) at week 12.
- To evaluate the impact of azathioprine in maintaining calprotectin remission (calprotectin levels < 200 ug/g) at week 48 and 96
- To evaluate the impact of azathioprine in maintaining calprotectin remission throughout a follow up period of 96 weeks.

Chronogram

Information to be collected	Data collection time points (96-week follow up)								
	Day 1	W12	W24	W36	W48	W60	W72	W84	W96 or discont. ⁴
Date of birth	X								
Sex	X								
Height	X								
Weight	X	X	X	X	X	X	X	X	X
BMI	X	X	X	X	X	X	X	X	X
Smoking status	X								
Medical history	X								
Comorbidities	X	X	X	X	X	X	X	X	X
CD presentation	X								
Diagnosis of CD - location, steroid behavior, prognostic classification, extra-abdominal manifestations, anal lesion)	X								
Clinical activity (HBI)	X	X	X	X	X	X	X	X	X
Colonoscopy (SES-CD)	X				X				X
Dose of azathioprine administered	X	X	X	X	X	X	X	X	X
Other therapies for CD	X	X	X	X	X	X	X	X	X
Concomitant therapies	X	X	X	X	X	X	X	X	X
Routine laboratory parameters ¹	X	X	X	X	X	X	X	X	X
Stool sampling ²	X	X	X	X	X	X	X	X	X
Reading of calprotectin levels by patient at home	X ³	X	X	X	X	X	X	X	X
Patient-reported outcomes (HBI)	X	X	X	X	X	X	X	X	X

¹ Hemoglobin, leukocytes, neutrophils, eosinophiles, basophiles, monocytes, lymphocytes, erythrocyte sedimentation rate, CRP, ferritin, iron and transferrin.

² The stool samples will be collected in the morning first stools by the patient at home. Samples will be collected using the CALEX tube AND the sample collector device.

³ the first reading by the patient will be performed during the first study appointment (Day 1) as part of the training procedures for stool sampling, preparation and reading.

⁴ If patient discontinues the observation period prior to week 96, the date of study discontinuation, the date of last intake of azathioprine and dose, and the reason for discontinuation should be recorded in the electronic CRF
W = week. HBI = Harvey Bradshaw Index. SES-CD = Simple endoscopic score for Crohn's disease.